ArticleCureus2025
Minimally-Invasive Conventional Right Colectomy Versus Complete Mesocolic Excision for Right-Colon Adenocarcinoma: A Single-Institution Cohort.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe benefits of complete mesocolic excision (CME) versus conventional right colectomy in right-sided colon cancer remain to be defined, as these relate to reduced nodal recurrence and increased disease-free survival (DFS). Optimal patient selection also appears crucial in selecting the best surgical technique for right colon cancer.
methodsA prospective, single-center database analyzing minimally invasive CME versus conventional colectomy in right-sided colon cancer was retrospectively analyzed. Only patients with free surgical margins and without distant metastases were included for analysis. The outcomes analyzed comprised local recurrence, nodal recurrence, DFS, length of stay, node harvesting, and major postoperative complications. The analysis was adjusted for multiple confounders, including age, sex, BMI, pathological T stage, pathological N stage, mismatch repair protein deficiency, adjuvant chemotherapy, first postoperative carcinoembryonic antigen (CEA) level, and American Society of Anesthesiologists Physical Status Classification System (ASA) score.
resultsCME presented a similar safety profile, with increased lymph node yield. CME was associated with a significant reduction in the risk of nodal recurrence (adjusted relative risk (RR) = 0.08; 95% CI: 0.05 to 0.09; p < 0.001). Moreover, in the propensity score matching (PSM) analysis, CME was associated with a significant coefficient of reduction for nodal recurrence (Coef. = -0.14; 95% CI: -0.23 to -0.05; p = 0.01). An improvement in DFS was also observed (hazard ratio (HR) = 0.03; 95% CI: 0.003 to 0.27; p = 0.002) in patients with pT3/pT4 or pN+ disease.
conclusionMinimally invasive CME may be associated with decreased nodal recurrence and increased DFS in patients with right colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.